Table of Contents

company-logo

Heron Therapeutics, Inc., a biotechnology company, engages in developing treatments to address unmet patient needs. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology, which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; HTX-019, an investigational agent for the prevention of postoperative nausea and vomiting; and HTX-034 for postoperative pain management, as well as is in Phase Ib/II clinical study in patients undergoing bunionectomy. The company was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. Heron Therapeutics, Inc. was founded in 1983 and is headquartered in San Diego, California.

Heron Therapeutics Dividend Announcement

• Heron Therapeutics does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Heron Therapeutics dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Heron Therapeutics Dividend History

Heron Therapeutics Dividend Yield

Heron Therapeutics current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Heron Therapeutics stock? Use our calculator to estimate your expected dividend yield:

Heron Therapeutics Financial Ratios

P/E ratio-6.23
PEG ratio0.83
P/B ratio-4.36
ROE76.79%
Payout ratio0.00%
Current ratio2.28
Quick ratio1.74
Cash Ratio0.30

Heron Therapeutics Dividend FAQ

Does Heron Therapeutics stock pay dividends?
Heron Therapeutics does not currently pay dividends to its shareholders.
Has Heron Therapeutics ever paid a dividend?
No, Heron Therapeutics has no a history of paying dividends to its shareholders. Heron Therapeutics is not known for its dividend payments.
Why doesn't Heron Therapeutics pay dividends?
There are several potential reasons why Heron Therapeutics would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Heron Therapeutics ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Heron Therapeutics has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Heron Therapeutics a dividend aristocrat?
Heron Therapeutics is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Heron Therapeutics a dividend king?
Heron Therapeutics is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Heron Therapeutics a dividend stock?
No, Heron Therapeutics is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Heron Therapeutics stocks?
To buy Heron Therapeutics you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Heron Therapeutics stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.